

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

Z-138

RRID:CVCL_B077

Type: Cell Line

Proper Citation

RRID:CVCL_B077

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_B077

Proper Citation: RRID:CVCL_B077

Description: Cell line Z-138 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Mantle cell lymphoma

Defining Citation: [PMID:9669839](#), [PMID:16183118](#), [PMID:16203034](#), [PMID:16960149](#), [PMID:21746927](#), [PMID:24362935](#), [PMID:25315077](#), [PMID:25688540](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26194763](#), [PMID:27697772](#), [PMID:29666304](#)

Comments: Miscellaneous: HLA*C loci for PubMed=24362935 was incorrect, modified version submitted by Pellat-Deceunynck, Catherine., Population: Caucasian., Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Z-138

Synonyms: Z138

Cross References: EFO:EFO_0005479, ATCC:CRL-3001, BioSample:SAMN03471023, cancercellines:CVCL_B077, ChEMBL-Cells:ChEMBL4483125, ChEMBL-Targets:ChEMBL4483276, Cosmic:2078183, Cosmic:2088021, Cosmic:2296992, Cosmic:2756238, GEO:GSM115807, GEO:GSM629502, GEO:GSM629503, GEO:GSM1044974, GEO:GSM1044975, GEO:GSM1044976, GEO:GSM1044977, GEO:GSM1266779, GEO:GSM1266780, GEO:GSM1266787, GEO:GSM1266788, GEO:GSM1266789, GEO:GSM1266790, GEO:GSM1266791, GEO:GSM1266792,

GEO:GSM2322624, Lonza:1605, Progenetix:CVCL_B077,
PubChem_Cell_line:CVCL_B077, Wikidata:Q54995848

ID: CVCL_B077

Record Creation Time: 20220427T221741+0000

Record Last Update: 20260830T000422+0000

Ratings and Alerts

No rating or validation information has been found for Z-138.

No alerts have been found for Z-138.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 61 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Sureda-G??mez M, et al. (2023) Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma. Leukemia, 37(2), 408.

Chen Y, et al. (2023) p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma. Experimental hematology & oncology, 12(1), 28.

Thus YJ, et al. (2023) Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation. Haematologica, 108(3), 797.

Jiang Z, et al. (2023) Ambra1 modulates the sensitivity of mantle cell lymphoma to palbociclib by regulating cyclin D1. Scientific reports, 13(1), 8389.

Dong Z, et al. (2023) Generation of a humanized afucosylated BAFF-R antibody with??broad activity against human B-cell malignancies. Blood advances, 7(6), 918.

Li L, et al. (2023) Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma. Haematologica, 108(6), 1616.

Zhang Y, et al. (2023) USP14 promotes the malignant progression and ibrutinib resistance of mantle cell lymphoma by stabilizing XPO1. International journal of medical sciences, 20(5), 616.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Quinet G, et al. (2022) Constitutive Activation of p62/Sequestosome-1-Mediated Proteophagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma. *Cancers*, 14(4).

Li J, et al. (2022) The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell Lymphoma. *Cancer control : journal of the Moffitt Cancer Center*, 29, 10732748221143881.

Erazo T, et al. (2022) TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma. *Nature communications*, 13(1), 5676.

Rico D, et al. (2022) High-resolution simulations of chromatin folding at genomic rearrangements in malignant B cells provide mechanistic insights into proto-oncogene deregulation. *Genome research*, 32(7), 1355.

Huang G, et al. (2022) USP9X Increased Tumor Angiogenesis in Mantle Cell Lymphoma by Upregulation of CCND1-Mediated SOX11. *Mediterranean journal of hematology and infectious diseases*, 14(1), e2022048.

Santos JC, et al. (2022) Antitumor Activity of Simvastatin in Preclinical Models of Mantle Cell Lymphoma. *Cancers*, 14(22).

Wang X, et al. (2022) CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia. *Leukemia*, 36(4), 1015.

Liu D, et al. (2022) Integrated analysis of 14 lymphoma datasets revealed high expression of CXCL14 promotes cell migration in mantle cell lymphoma. *Aging*, 14(8), 3446.

Gu P, et al. (2022) Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors. *Frontiers in oncology*, 12, 885186.

Luanpitpong S, et al. (2022) Bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell Lymphoma. *International journal of molecular sciences*, 23(22).

Bewarder M, et al. (2021) The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells. *HemaSphere*, 5(8), e620.

Panaampon J, et al. (2021) Establishment of Nude Mice Lacking NK Cells and Their Application for Human Tumor Xenografts. *Asian Pacific journal of cancer prevention : APJCP*, 22(4), 1069.